Double-blind study of oral gamma-vinyl GABA in the treatment of dystonia.
Six patients with different forms of dystonia were treated with gamma-vinyl GABA, a specific enzyme-activated inhibitor of GABA-transaminase, in a double-blind, placebo-controlled crossover study. gamma-Vinyl GABA therapy, 2 g daily for 2 weeks, was compared with placebo by weekly assessments. There were no consistent changes in three evaluation scores. Agents that augment CNS GABA are unlikely to benefit patients with generalized dystonia.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000614:Aminocaproates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004421:Dystonia / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009068:Movement; D012720:Severity of Illness Index; D020888:Vigabatrin
D000614:Aminocaproates; D020888:Vigabatrin